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Abstract 
The use of theranostics in neurosciences has been rare to date because of the limitations imposed 
on the free delivery of substances to the brain by the blood-brain barrier. Here we report the 
development of a theranostic system for the treatment of stroke, a leading cause of death and 
disability in developed countries. We first performed a series of proteomic, immunoblotting and 
immunohistological studies to characterize the expression of molecular biomarkers for the 
so-called peri-infarct tissue, a key region of the brain for stroke treatment. We confirmed that the 
HSP72 protein is a suitable biomarker for the peri-infarct region, as it is selectively expressed by 
at-risk tissue for up to 7 days following cerebral ischemia. We also describe the development of 
anti-HSP72 vectorized stealth immunoliposomes containing imaging probes to make them 
traceable by conventional imaging techniques (fluorescence and MRI) that were used to encap-
sulate a therapeutic agent (citicoline) for the treatment of cerebral ischemia. We tested the 
molecular recognition capabilities of these nano-platforms in vitro together with their diagnostic 
and therapeutic properties in vivo, in an animal model of cerebral ischemia. Using MRI, we found 
that 80% of vectorized liposomes were located on the periphery of the ischemic lesion, and an-
imals treated with citicoline encapsulated on these liposomes presented lesion volumes up to 30% 
smaller than animals treated with free (non-encapsulated) drugs. Our results show the potential of 
nanotechnology for the development of effective tools for the treatment of neurological diseases. 
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Introduction 
Nanomedicine is a discipline that offers new and 
exciting tools for the medical field, such as 
theranostics, that enable the development of the con-
cept of personalized medicine. Theranostics consist of 
the design, construction and use of molecular plat-
forms with dual diagnostic and therapeutic roles. 
Such nano-platforms include imaging probes for the 








specific cell populations or cellular functional states in 
vivo and, at the same time, promoting the stabiliza-
tion, transport and controlled release of these drugs at 
targeted sites by virtue of including therapeutics in 
their structure [1]. In this way, theranostics represents 
a perfect marriage between molecular imaging and 
targeted drug delivery technologies in a single mo-
lecular platform. Exciting examples of theranostic 
applications have been reported for cancer [2], ather-
osclerosis [3], and gene therapy [4], among others.  
The incidence of neurological diseases is rapidly 
increasing in developed countries due to the progres-
sive aging of their population, representing a huge 
burden for society [5]. In this sense, theranostics may 
offer new and stimulating opportunities for the de-
velopment of novel treatments in this field. However, 
most of the reported applications for theranostic 
agents imply the action of these agents at a vascular 
level (e.g., atherosclerosis) or in tissues with high 
vascular density and permeability (e.g., tumors). 
Theranostic approaches for targets located inside the 
brain are rare due to the difficulties experienced by 
systemically administered substances in crossing the 
blood-brain barrier (BBB), the functional structure 
that tightly controls the efflux of substances from and 
to the brain [6].  
In terms of stroke, one of the leading causes of 
mortality and morbidity in developed countries, it is 
noteworthy that treatment by recanalization therapies 
is currently limited to less than 5% of patients admit-
ted to hospitals (though this figure may be higher in 
centers with specialized stroke units) [7]. We believe 
that, despite the challenge represented by crossing the 
BBB, theranostics may help us to provide a better 
understanding of the underlying molecular mecha-
nisms of this devastating disease, enabling the de-
velopment of future treatments at the clinical level.  
Ischemic stroke consists of a rapid loss of cere-
bral function as consequence of the obstruction of a 
brain vessel, followed by subsequent damage to 
neighboring tissue. Cerebral tissue quickly becomes 
irreversibly damaged in the vicinity of the closed 
vessel (this region is known as the infarct core), but 
tissue is potentially salvageable towards the periph-
ery of the lesion (in an area known as the peri-infarct 
region). Tissue at the peri-infarct region represents a 
key target for the development of new treatments 
against stroke, especially at sub-acute and chronic 
phases of this disease, for which no effective therapies 
are currently available [8, 9]. 
Here we report the development of a novel 
theranostic nanocarrier that specifically targets the 
peri-infarct tissue in cerebral ischemia. This is one of 
the few reports that includes a complete set of in vitro, 
in vivo and ex vivo studies of the design and testing of 
the diagnostic and therapeutic capacities of a novel 
theranostic nano-platform for cerebral ischemia. This 
study demonstrates that theranostics beyond the 
blood-brain barrier is feasible and represents an ex-
ample of the potential that nanotechnology offers for 
the treatment of neurological diseases. 
Theranostic targets for ischemic stroke  
The peri-infarct region is a complex and contin-
uously evolving portion of the ischemic brain that is 
difficult to delineate with conventional imaging tech-
niques. Theranostics may provide an effective way to 
define this region in detail through molecular recog-
nition processes [6, 8, 9].  
The selection of a biomarker that unequivocally 
characterizes the targeted tissue is a key step in the 
design of a theranostic agent [6]. A handful of pub-
lished literature has reported the upregulation of par-
ticular proteins in the periphery of an ischemic lesion 
[10-16], but comparisons of their appropriateness as 
biomarkers cannot be extracted from individualized 
analyses. Thus, we conducted a complete proteomic, 
immunoblot and immunohistological study (sche-
matically described in figure 1), in order to achieve a 
full characterization of protein expression at the pe-
ri-infarct region in an animal model of cerebral is-
chemia. Once a suitable target was selected, we per-
formed a spatiotemporal description of its expression 
for a period of 14 days following the induction of the 
lesion. 
For this purpose, a permanent focal cerebral is-
chemia was induced in 6 rats (see methods), extract-
ing and processing their brains (t= 48 h port surgery) 
to identify the ischemic core by staining necrotic tis-
sue with 2,3,5-triphenyl-tetrazolium chloride (TTC, 
white staining in figure 1a). Strips of tissue (2 mm 
thick) were dissected around the infarct core (consid-
ered peri-infarct tissue) and in the contralateral brain 
hemisphere (considered control tissue). Proteins from 
both tissue sections were extracted and separated into 
membrane, soluble and insoluble protein fractions 
(see methods below). 2D-Gel electrophoresis was 
performed on 2 sets of polyacrylamide gels (pe-
ri-infarct vs. healthy tissue), separating proteins by 
their isoelectric points and molecular weights (figure 
1b). Paired comparisons (peri-infarct vs. control) of 
stained spots in gels (n=962, 1632 and 814 spots found 
for membrane, insoluble and soluble protein fractions, 
respectively) were analyzed, revealing 11 significant 
differences in protein expression at the peri-infarct 
tissue with respect to control tissue. The most robust 
difference (peri-infarct/control tissue ratio of expres-
sion > 20) corresponded to the 70 kDa family of Heat 
Shock Proteins (arrows in figure 1b). 





Fig 1. a) Infarct core of a section of an ischemic rat brain stained (in beige) by tetrazole chloride. A 2 mm strip around this area (dotted line) and a mirrored 
contralateral section were selected as peri-infarct and control tissues, respectively. Following tissue disaggregation, proteins were isolated in 3 fractions (insoluble, 
soluble and membrane proteins). 2D-PAGE analysis was performed, and proteins over-expressed in the peri-infarct tissue were evaluated by Western blot (WB) and 
immunohistochemistry (IHC). b) Proteomic gels showing the expression of peri-infarct and contralateral proteins (spots) with magnification (red frames) of the 
region where HSP70 proteins is located. c) 2D-WB results showing (top row) that HSP72 (circled in red) is the only member of the HSP70 family specifically 
expressed at the peri-infarct tissue, while other members of the family are also expressed in contralateral tissues (actin bands used for protein load control are also 
shown). d) Immunohistochemical (IHC) study of consecutive brain slices (10 µm) stained for HSP72 (top-row), HSC70 (middle-row) and GFAP (bottom-row). 
Left-to-right columns: complete brain slices, 4X magnifications of the ischemic and contralateral hemispheres, and a 10X magnification of the peri-infarct region. e) 
Double fluorescence IHC of peri-infarct tissue. HSP72 (red) is mostly expressed by neurons (NeuN green, top) but not by astrocytes (GFAP green, bottom), 48 h 
after ischemia. f) Temporal profile of HSP72 expression in the ischemic brain. Regions selected for cell counting analysis are indicated in the MR image (where infarct 
core appears hyper-intense). g) Color-coded density maps (overlaid on MR images) presenting the spatiotemporal expression profile of HSP72 in the ischemic brain. 




Following 2D Western-blotting (figure 1c), iso-
lated HSP70 protein bands were stained with a mon-
oclonal anti-HSP70 antibody (using β-actin as the 
protein load control). A fraction of this family, known 
as the constitutive form of HSP70 (or HSC70), was 
equally expressed in both peri-infarct and healthy 
tissues, so it was not suitable as targeting vector. 
However, a small fraction of this family, identified as 
the HSP72 protein (or inducible form of HSP70), was 
specifically expressed at the peri-infarct tissue (circled 
spot in figure 1c) and selected as a specific target for 
the peri-infarct tissue.  
These results were confirmed by immunohisto-
chemical studies (figure 1d) that revealed the specific 
expression of HSP72 in the peri-infarct region (top 
row in figure 1d), while HSC70 is constitutively ex-
pressed in the whole brain, although higher expres-
sion of this protein can be found in the peri-infarct 
tissue (middle row in figure 1d). The infarct core was 
delineated as the area with a very low density of cells, 
surrounded by an accumulation of glial cells in the 
periphery (GFAP staining, bottom row in figure 1d) as 
previously described [17].  
Double-fluorescence immunohistochemistry 
studies (figure 1e) confirmed that HSP72 (red fluo-
rescence) is mainly expressed by neurons in the is-
chemic brain, 48 hours after surgery (Green NeuN 
fluorescence in the top image). Astrocytes, in contrast, 
did not significantly express the protein at this time 
point (Green GFAP fluorescence in the bottom image). 
We analyzed these two cell types because they repre-
sent the major fraction of brain cell populations. 
However, few other scattered cells were also positive 
for HSP72, and we cannot rule out the possibility that 
microglia, endothelial cells or other cell types also 
exhibit some degree of HSP72 expression using cur-
rent ICH material. It should be mentioned that the 
type of brain cells expressing HSP72 is dependent on 
the time after ischemia [13]. 
The fact that HSP72 is mostly a cytosolic protein 
may be a concern with respect to its suitability as a 
target for molecular recognition processes with 
theranostic molecules. However, under stress condi-
tions, such as hyperthermia or ischemia, HSP72 has 
been shown to translocate to the membrane and is 
even released into the extracellular space [18, 19]. 
Thus, we believe that the HSP72 protein can still be 
considered a valid target for theranostic molecules (as 
we demonstrate later in our in vitro studies).  
Brains sections obtained at 6 h, 12 h and 1, 2, 3, 5, 
7, 10 and 14 days after surgery were processed to es-
tablish a spatiotemporal profile of expression of 
HSP72 in the ischemic brain. The number of 
HSP72-positive cells was quantified in 2 square re-
gions located in the infarct core (as delineated by dif-
fusion-weighted or T2-weighted MR images) and in 
another 2 regions in its periphery (figure 1f). During 
the first hours of lesion evolution, MR images show a 
hyperintense region on the diffusion-weighted imag-
es, which is generally accepted as the lesion core. 
However, this hyperintense area includes necrotic 
cells as well as surviving cells that usually die after a 
period of time by different molecular mechanisms 
(such as apoptosis). Additionally, it has been reported 
that HSP72 is absent in dead neurons in necrotic tis-
sue, but the protein can be found in surviving glia and 
in the microvasculature [13]. Thus, high expression of 
HSP72 was found in the core during the first 12 h of 
the evolution of the lesion, followed by a rapidly drop 
after this period, when the whole region becomes ne-
crotic. Damage to the surrounding tissue, the pe-
ri-infarct region, progresses in a slower fashion, 
reaching maximum HSP72 expression at 24-72 h post 
ischemia (figure 1f) and lasting for a period of one 
week. The number of positive cells beyond this time 
point presented large variability, and observed values 
are not statistically significant. 
Using the numeric values presented in figure 1f, 
we were able to construct density maps of HSP72 ex-
pression in the ischemic brain over a period of 2 
weeks (figure 1g). The high and specific upregulation 
of HSP72 in the peri-infarct tissue during a period of 
24 h to 7 days qualifies this protein as a suitable target 
for theranostic molecules in the treatment of stroke at 
the subacute phase of the disease. 
Theranostic nanoplatforms  
Several types of nanosystems (e.g., peptides, 
dendrimers or liposomes) have the potential to be 
used as theranostic agents [20-27]. We used liposomes 
as the synthetic basis for our agent because they are 
very well-known biocompatible drug carriers, with 
the capacity to effectively cross the BBB when their 
size is controlled [28, 29]. In addition, liposomes are 
useful for proof-of-principle purposes, and the prep-
aration of these self-assembling systems is affordable 
in research laboratories with limited synthetic capaci-
ties, which is an important issue, considering a po-
tential translationality of our methodology to clinical 
practice.  
Thus, stealth cholesterol/DSPC liposomes were 
prepared as reported elsewhere [30] (see methods for 
further details), including a fraction of 
PEG-conjugated lipids to avoid in vivo aggregation, 
opsonization and rapid clearance from blood by the 
reticuloendothelial system [20, 31-34]. The size of lip-
osomes was limited to circa 100 nm by extrusion. This 
size is large enough to allow the entrapment of ther-
apeutic doses of a drug, while still allowing passage 
across the BBB by different molecular mechanisms, as 




has been reported in the literature [6, 29, 35]. The 
transient opening of the BBB that takes place after 
cerebral ischemia may also facilitate the access of lip-
osomes to the brain parenchyma. 
Characterization of liposomes by dynamic light 
scattering (DLS) and transmission electronic micros-
copy (TEM) techniques (see methods) indicated the 
formation of small unilamellar vesicles (SUVs) with a 
narrow distribution of hydrodynamic radii around 
100 nm (figure 2). Liposomes were stored at 4°C and 
remained stable for at least 4 days (figure 2b, <7% 
aggregation), which is an important factor in the per-
formance of longitudinal in vivo studies.  
Following a multimodal approach [36, 37], 
phospholipids containing rhodamine or gadolinium 
were used for the preparation of liposomes to make 
them traceable by fluorescence and magnetic reso-
nance imaging (MRI) techniques, enabling their use as 
diagnostic tools. Detectability by fluorescence was 
tested with cultured astrocytes transfected with (red) 
rhodamine-loaded liposomes (Figure 3). Liposomes 
were also detectable in vivo by MRI as hyperintense 
areas on R1 parametric maps (R1 = 1/T1) or hy-
pointense areas on T2-weighted MR images, as a 
consequence of a reduction of longitudinal (T1) and 
transversal (T2) relaxation times induced by the gad-
olinium carried by liposomes (Figure 3). 
 
 
 Fig 2. a) CryoTEM micrograph of liposomes showing the formation of (mostly) unilamellar vesicles, and magnification of a single liposome. b) Liposome sizes 
(measured by Dynamic Light Scattering) are homogeneous (~100 nm) and remain stable (at 4˚C) for at least 4 days (<7% of large aggregates at this time point).  
 





Fig 3. Top: fluorescence images of cultured astrocytes transfected with liposomes, showing red fluorescence due the rhodamine content of liposomes. Liposomes do 
not penetrate cell nuclei (blue Hoechst staining). Bottom: MR T2-weighted images (left) and R1 (=1/T1) parametric maps of a rat brain 24 hours after in-
tra-parenchymal injection of liposomes. The presence of gadolinium in liposomes enables their detection as hypointense areas on T2w images and hyperintense 
regions on R1 maps.  
 
 
Furthermore, citicoline (CDP-Choline), a drug 
used in the treatment of stroke [30, 38], was encapsu-
lated in the liposomes for therapeutic purposes. We 
previously optimized citicoline encapsulation for our 
particular liposomal composition and size [30], 
achieving a drug content of 8% in weight with an en-
capsulation efficiency of 1.5 ml/mmol. 
Synthesis of the theranostic nano-platform end-
ed with the vectorization of liposomes against HSP72, 
a specific molecular biomarker of the peri-infarct re-
gion. The covalent union of HSP72 antibodies to lip-
osomes was achieved by the formation of thioether 
bonds between the maleimide groups present in 
PEGylated phospholipids and thiol groups from 
SATA-modified amino acids in HSP72 antibodies, as 
described elsewhere [37]. The efficiency achieved in 
this step was 64% (as determined by the Lowry 
method) [39]. Finally, we used the method described 
by Hutchinson et al. [40] to estimate that each lipo-
some contained 12 anti-HSP72 units attached to its 
surface. For the calculations, we used a molar ratio of 
anti-HSP72/lipids of 3.13 10-4/1 (used in the synthesis 
of liposomes), a protein molecular weight of 160 kDa, 
a liposome radius of 50 nm, an area per lipid molecule 
in the liposomal bilayer of 0.50 nm2 [40], and effi-
ciency of protein coupling to liposomes of 64%.  
Molecular recognition of targeted cells 
Molecular recognition of HSP72-vectorized lip-
osomes was tested using an in vitro model. At this 
point it is not particularly relevant which cell type or 
culture conditions are used, because our sole intention 
was to demonstrate that synthetized HSP72-targeting 
liposomes can effectively participate in molecular 
recognition processes with cells that express that 
protein. Following a model previously described in 
literature, we found that cultures of rat astrocytes 
subjected to stress by hyperthermia showed a notice-
able expression of HSP72 protein [41], making them a 
good model for our purposes. 
Primary cultures of astrocytes were obtained 
from the brains of 1-day-old rats (see methods), sub-
jecting one set of cells to a thermal shock (42 °C, 30 
min), followed by a resting period of 6 hours under 
regular conditions (37 °C, 5% CO2) to induce the ex-
pression of HSP72 [41]. A set of cells was maintained 
in parallel under normal conditions as controls. Both 
sets of cells were incubated for 30 min with regular 
(non-targeted) and anti-HSP72 vectorized liposomes 
in all four possible combinations as follows: 1) control 
cells + control liposomes, 2) control cells + vectorized 
liposomes, 3) HSP72 expressing cells + control lipo-
somes, and 4) HSP72 expressing cells + vectorized 
liposomes (figure 4a). 
Cells tagged with the rhodamine contained in 
liposomes were only observed when HSP72 positive 
cells were combined with anti-HSP72 vectorized lip-
osomes. No other liposomes-cell combinations pre-
sented fluorescence under the microscope (figure 4a).  





Fig 4. a) Fluorescence images of cell cultures of HSP72-positive and negative cells incubated for 30 min with anti-HSP72 vectorized or with regular (non-targeting) 
fluorescent liposomes. Only the incubation of HSP72-positive cells with anti-HSP72 vectorized liposomes led to the observation of significant fluorescence (molecular 
recognition). b) T1 parametric maps (and quantification of T1 relaxation times) of cell pellets obtained from the previously described cell cultures using a 9.4 Tesla 
MRI system. Only the incubation of HSP72-positive cells with anti-HSP72 vectorized liposomes led to the observation of a significant reduction of T1 relaxation times. 
 
Cell pellets were collected from all cultures by 
centrifugation and, after removing the supernatant 
fluid, the corresponding parametric maps of the lon-
gitudinal relaxation times (T1) of the pellets were ob-
tained on a MR scanner at 9.4 T (figure 4b). Combina-
tions of anti-HSP72 vectorized liposomes with 
HSP72-positive cells presented a significantly reduced 
T1 value (T1=2.69 s) with respect to all the other 
studied cell-liposome combinations, including the 
culture medium used as a control (ANOVA, p<0.05). 
Fluorescence and MRI studies confirmed the ef-
fective molecular recognition of anti-HSP72 vector-
ized liposomes by HSP72-expressing cells. 




Diagnostic function of theranostic nano-
platforms  
The capacity of the theranostic agent to delineate 
the peri-infarct tissue in ischemic animals in vivo (di-
agnostic function) was assessed in 12 ischemic rats, 
randomly divided in 3 groups receiving 6 intravenous 
injections of v=1 ml (at t=45 min and 6, 12, 18, 24, 30 h 
after surgery) of one of the following: (1) saline (con-
trol group), (2) regular (non-vectorized) liposomes, or 
(3) HSP72-vectorized liposomes. In those groups of 
animals treated with liposomes, a total concentration 
of 24 µmol/ml of lipids was used. MR longitudinal 
relaxation (T1) maps of their brains were obtained 1 
day before and 1, 3 and 7 days post-surgery (see 
methods). Images were processed (see methods and 
figure 5 for a detailed description of image analysis) to 
display regions of abnormally reduced T1 relaxation 
times assigned to areas where liposomes doped with 
gadolinium are present. It is important to remember 
that liposomes reduce T1 relaxation times (as shown 
in figure 4b and in the histogram presented in figure 
5a). Representative images showing the distribution 
of liposomes in the brain of ischemic rats 24 h after 
systemic injection of liposomes are presented in figure 
6. Saline-treated animals showed no R1-enhanced 
areas (except for some scattered pixels that may cor-
respond to fitting noise), while anti-HSP72 vectorized 
liposomes show highlighted areas in the periphery of 
the ischemic lesion. Interestingly, regular 
(non-targeted) liposomes appear to be randomly dis-
tributed along both brain hemispheres (figure 6). An 
immunohistological image of HSP72 expression in the 
ischemic brain (figure 6) shows that the in vivo dis-
tribution of liposomes (as seen on MR images) pre-
sents a considerable degree of correlation with the ex 
vivo expression of the protein, corroborating the mo-
lecular recognition capacity of the theranostic agent 
and its diagnostic capabilities. In Figure 6, although 
there is a high expression of HSP72 in a thin strip 
around the lesion upper corner, a closer look at the 
histological image suggests the overexpression of the 
protein in a wider region around the ischemic lesion, 
as seen on MRI images. However, the sensitivity of 
both techniques is very different, and a direct correla-
tion between the expression of protein and liposome 




Fig 5. a) Histogram of T1 values corresponding to healthy tissue (pink), 
ischemic tissue (blue) and tissue containing Gd-doped liposomes (green) (the 
last obtained after an intra-parenchymal injection of liposomes into healthy 
animals). b) Image processing to obtain the following distribution maps of 
liposomes: (1) Manually segmented T1 maps obtained from saturation-recovery 
MRI studies. (2) Color encoding of maps. (3) Image smoothing (r=0.6 Gaussian 
filter). (4) Clipping process to remove pixels with T1>2.25 s (thresholding). (5) 
Color re-scaling. (6) Overlaying of maps on corresponding proton density MR 
images. (7) Clustering process to eliminate groups of n< 3 pixels (considered 
noise).  





Fig 6. Representative MR images of ischemic brains from rats treated (i.v.) with 1 ml of saline (top left), regular (non-vectorized) liposomes (top right) or anti-HSP72 
vectorized liposomes (bottom left) showing the in vivo distribution of liposomes 24 h after treatment. An immunohistological image of HSP72 protein expression 
(bottom right) shows good agreement between the in vivo locations of liposomes with the areas of expression of HSP72 observed ex vivo. 
 
 
Fig 7. a) Plot showing the percentage of the total amount of liposomes (image 
pixels of reduced T1 values on parametric maps) found in the ipsilesional 
hemisphere with respect to the total amount of liposomes found in the entire 
brain. Differences between regular liposomes (evenly distributed on both 
hemispheres) and HSP72-targeting liposomes (mostly located at the infarcted 
hemisphere) are significant between both groups at all studied time points (1, 3 
and 7 days post injection), but no significant differences were found within 
groups. (*, $ and # represent p<0.05). b) Plot showing the percentage of pixels 
that contain liposomes (image pixels of reduced T1 values) with respect to the 
total amount of pixels of the brain MRI. Liposomes levels were relatively higher 
for regular liposomes on day 1 and for targeting liposomes on day 7. No 




Furthermore, in an attempt to quantify the ten-
dency of HSP72-targeting liposomes to accumulate in 
the peri-infarct region, we measured the number of 
highlighted pixels in each brain hemisphere (the 
number of pixels w 
ith T1 values lower than 2.25 s, see methods and 
figure 5a). Figure 7a shows the percentage of all 
counted pixels that are located in the left (ischemic) 
hemisphere with respect to the total number of pixels 
found in the whole brain of the animals. For an-
ti-HSP72 liposomes, the percentage of pixels with 
reduced T1 times (attributed to the presence of lipo-
somes) in the affected hemisphere ranged between 
70-80%, at day 1, 3, and 7, while regular liposomes 
appear to be equally distributed between both brain 
hemispheres (figure 7a). 
On the other hand, the percentage of the total 
number of pixels of the brain that presented a reduced 
T1 value (a rough estimation of the amount of lipo-
somes that reach the brain) was similar for both 
groups and ranged between 9 to 17% (figure 7b). On 
day 1, there was no significant difference between 
vectorized and non-vectorized liposomes (14.32±1.9 
vs. 12.58±0.81), while the percentage of brain pixels 
that contain liposomes was higher for control lipo-
somes on day 3 (17.43±1.62 vs. 11.89±1.76), and higher 
for targeted liposomes on day 7 (9.46±1.58 vs. 
15.67±1.35). 




These studies demonstrate the capacity of 
HSP72-targeted liposomes to delineate and follow the 
evolution of the peri-infarct tissue in vivo, confirming 
the diagnostic functionality of theranostic liposomes. 
Therapeutic function of theranostic na-
noplatforms 
The therapeutic capacity of the theranostic agent 
was demonstrated with a second in vivo study. Qual-
itatively speaking, the therapeutic effects of citicoline 
(CDP-Choline, a therapeutic agent that reduces lesion 
volumes in this animal model) [30, 38, 42] were highly 
increased by encapsulation of the drug in 
HSP72-targeted liposomes. Animals treated with cit-
icoline-loaded HSP72 targeting liposomes presented 
reduced lesion volumes on T2 parametric maps 
compared to untreated animals or animals treated 
with the free (non-encapsulated) drug (figure 8a).  
 
Fig 8. a) 3D color-coded MR parametric maps of transverse relaxation times (T2) of the brain of 3 ischemic rats, 7 days after treatment (i.v.) with saline (left), free 
CDP-Choline (center), or CDP-Choline encapsulated in HSP72-targeting liposomes (right). b) Plot showing the evolution of the lesion sizes of ischemic animals 
previously to and during the 7 day post-treatment period with intravenous injections of saline (white), empty liposomes (light grey), an intraperitoneal injection of 
CDP-choline (left-tilted bars), or intravenous injections of free CDP-choline (dark grey), CDP-choline encapsulated in regular liposomes (right-tilted bars) or 
CDP-choline encapsulated in HSP72-targeted liposomes (black). In this plot, (*) represents significant differences (p<0.05) found by ANOVA for all groups of animals, 
while (#) represents significant differences (p<0.05) based on Student’s t-test between selected pairs of groups.  





Fig 9. Ex vivo fluorescence microscopy images of the peri-infarct region of animals obtained 7 days after intravenous injections of CDP-choline encapsulated in 
anti-HSP72 vectorized liposomes. Rhodamine fluorescence (red) confirms the presence of the theranostic agent in the brain parenchyma (cell nuclei stained in blue 
with Hoescht). 
 
Quantitation of the superior therapeutic effect 
offered by the theranostic agent was performed via a 
study in which 24 Sprague-Dawley rats were given to 
a permanent focal cerebral ischemia and randomized 
into 6 groups of n=4 rats. One group (group 3 in fig-
ure 8b) was treated with a single intraperitoneal in-
jection of 500 mg/kg body weight of citicoline (de-
scribed as an effective neuroprotective dose for is-
chemic rats) [30]. The other 5 treatment groups re-
ceived 6 (t= 45 min, 6, 12, 24 and 30 h post-surgery) 
intravenous injections (jugular vein) of v=1 ml of sa-
line (group 1), empty liposomes (group 2), a dose of 8 
mg/kg body weight of citicoline dissolved in saline 
(group 4), and the same amount of citicoline encap-
sulated in regular liposomes (group 5) or encapsu-
lated in HSP72-targeted liposomes (group 6). Diffu-
sion-weighted imaging (pre-treatment) or 
T2-weighted MR imaging (days 1, 3 and 7 
post-treatment) were used to quantify the lesion 
volumes for all animals (see methods). 
Before treatment, measured lesion volumes 
(figure 8b) were comparable for all groups (Vt=0= 
147±45, 148±24, 159±15, 155±41, 147±15 and 146±11 
mm3 for groups 1, 2, 3, 4, 5 and 6, respectively). As 
expected for this animal model [43, 44], the lesion 
volumes of control animals increased, reaching their 
maximum values at day 3 post surgery and dropping 
to intermediate values at day 7 (Vgroup 1= 215±67, 
220±77 and 201±50 mm3 at days 1, 3 and 7). The re-
sults were not significantly different for animals 
treated with empty liposomes or an i.p. injection of 
citicoline (ANOVA test, p<0.05). However, intrave-
nous injections of free citicoline (group 4) or citicoline 
encapsulated in regular liposomes significantly re-
duced lesion volumes on day 7 (Vgroup4= 122±19 and 
Vgroup5= 82±17 mm3, respectively, vs. Vgroup1= 201±50 
mm3 for controls; p<0.05). The highest therapeutic 
effect was achieved when citicoline was encapsulated 
in HSP72-targeting liposomes, which resulted in sig-
nificantly smaller lesion volumes compared to con-
trols at day 1 (Vgroup6= 116±18 vs. Vgroup1= 215±67 
mm3), day 3 (Vgroup6= 106±12 vs. Vgroup1=220±77 mm3) 
and day 7 (Vgroup6=55±16 vs. Vgroup1=201±50 mm3) and 
compared to citicoline encapsulated in regular lipo-
somes at day 7 (Vgroup6= 55±16 vs. Vgroup5= 82±17 
mm3).  
The presence of HSP72-targeted liposomes in the 
peri-infarct tissue in the brain was confirmed by ex 
vivo fluorescence microscopy of tissue sections ob-
tained on day 7 (figure 9). In this figure, red rhoda-
mine (from liposomes) was detected in a few cells of 
peri-infarct tissue (nuclei stained in blue), although 
the current data cannot provide information about 
which particular type of cell is positive for rhodamine. 
In any case, those pictures show that it is feasible for a 
load of treatment to reach the brain parenchyma after 
an intravenous injection of liposomes. 
Conclusions 
In this study we report a new theranostic 
nano-platform vectorized towards peri-infarct tissue, 
a key target for the treatment of cerebral ischemia. The 
selection of the HSP72 protein as a selective targeting 
vector was made after a complete characterization of 
protein expression in the ischemic brain. Anti-HSP72 
stealth immunoliposomes containing a load of citico-
line and fluorescence and MR imaging probes were 
used to delineate the peri-infarct region in vivo (di-
agnostic function) and to achieve a superior thera-
peutic effect in comparison to other non-targeted drug 
delivery means. Thus, despite the challenge of cross-
ing the blood-brain barrier, this study demonstrates 




that theranostics inside the brain parenchyma is fea-
sible and represents a good example of the potential 
that nanotechnology offers for the treatment of neu-
rological disorders such as stroke. 
Methods 
Animal studies 
All experimental protocols involving the use of 
research animals were performed according to the 
guidelines of the Animal Welfare Committee of our 
host institution and were in accordance with applica-
ble legislation of the European Union (DC 
86/609/EEC, 2003/65/EC, 2010/63/EU). Studies 
were designed and conducted according to the fol-
lowing Stroke Therapy Academic Industry 
Roundtable group guidelines (STAIR) criteria: 1) 
Monitoring: the temperature of the animals was con-
tinuously monitored and corrected during surgery. 
Blood glucose levels were recorded prior to surgery. 
A laser Doppler blood flow-meter was used to meas-
ure cerebral blood flow during surgery. 2) Randomiza-
tion: all animals were randomly assigned to treatment 
groups. 3) Allocation concealment: the scientist per-
forming the surgery or treatment application was 
blinded to the procedures. Scientists acquiring images 
on MR were also blinded to procedures. 4) Blinded 
assessment of outcome: scientists performing the image 
analysis and outcome assessment were blinded to all 
surgical procedures and treatment applications. 5) 
Conflict of interest: all potential conflicts of interest 
and study funding have been reported on this manu-
script. 
A total of 72 male Sprague-Dawley rats (Harlan 
Laboratories, Barcelona, Spain) weighing 348±63 g 
were used in this study. Animals were kept in a con-
trolled environment at 22±1 °C and 60±5% humidity 
with 12/12 h light/darkness cycles, and were fed ad 
libitum with standard diet pellets and tap water. All 
surgical procedures and MRI studies were conducted 
under Sevofluorane (Abbott Laboratories, IL, USA) 
anesthesia (3-4% carried by a 65:35 mixture of N20:02). 
Permanent focal cerebral ischemia was induced by an 
intracranial occlusion of the left middle cerebral artery 
(MCA) following the method of Shigeno et al. [45] as 
described elsewhere [30]. When required, intravenous 
injections of typically v=1 ml were administered in the 
jugular vein (alternating left and right jugular veins 
for treatments requiring multiple injections) of anes-
thetized animals with a 30 gauge needle. Animals 
were sacrificed at the end of the studies by exposure 
to a lethal dose of Sevofluorane (8%). 
Synthesis and Characterization of liposomes 
Liposomes were prepared by the lipid film re-
hydration method [30, 46]. Mixtures of lipids (typi-
cally 24 µmol) were prepared in a 6:1 v/v mixture of 
chloroform: methanol (Panreac Química, Barcelona, 
Spain). The mixtures contained cholesterol (molar 
fraction: x=0.33), 1,2-dioctadecanoyl-sn-glycero- 
3-phosphocholine (DSPC: x=0.57), diethylenetriamine 
pentaacetic acid)-bis(stearylamide) gadolinium salt 
(Gd-DTPA-BSA: x=0.03), 1,2-distearoyl-sn-glycero- 
3-phosphoethanolamine-N-[amino(polyethyleneglyco
l)-2000] (ammonium salt) (PEG-DSPE: x=.05 in regular 
and x=.025 in vectorized liposomes), 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[
maleimide(polyethylene glycol)-2000] (ammonium 
salt) (Mal-PEG-DSPE: x=0.025, only in vectorized lip-
osomes), and 1,2-dioleoyl-sn-glycero-3-phosphoetha-
nolamine-N-(lissamine rhodamine B sulfonyl) am-
monium salt (Liss Rhodamine PE, 0.1% w/w). All 
products were obtained from Avanti Polar Lipids, AL, 
USA. 
After evaporation of the organic solvent on a 
rotavapor operated under vacuum at 30°C and over-
night drying under a nitrogen flow, the lipid films 
formed were hydrated in HEPES-buffered saline 
(HBS, 10 mM HEPES, 135 mM NaCl, pH 7.4) at 65°C. 
Liposomes were then extruded in a Lipex Extruder 
(Northern Lipids, B.C., Canada), keeping the mixture 
at 65°C at all times. Liposomes were consecutively 
extruded 2, 4, 6 and 8 times through 400-, 200-, 100- 
and 80-nm polycarbonate membranes, respectively 
(Whatman, GE Healthcare, WI, USA). The final vol-
umes were adjusted with HBS to achieve the desired 
total concentrations of lipids. 
The total lipid concentrations in liposomes were 
determined based on phosphate quantification ac-
cording to Rouser et al [47]. The liposome protein 
content (vectorized liposomes) was determined using 
the Lowry protocol [39] as described elsewhere [46]. 
The distribution of liposome sizes in solution (hy-
drodynamic diameters) was determined by dynamic 
light scattering (DLS, ZetaSizer NanoS, Malvern In-
struments, Worcestershire, UK) at 23°C. 
Liposomal solutions were vitrified on car-
bon-coated grids using a Vitrobot Mark III (FEI, OR, 
USA) for cryogenic transmission electron microscopy 
(cryo-TEM), and 25000X images were acquired on a 
Tecnai 20 Sphera TEM instrument (FEI, OR, USA) 
equipped with a LaB6 filament (200 kV) and Gatan 
cryoholder (-170°C). 
Protein conjugation to liposomes 
Regular liposomes were prepared as described 
above using a molar fraction of x=0.025 of maleimide 
containing PEGylated phospholipids 
(Mal-PEG-DSPE). In parallel, azide-free antibodies 
were obtained by three successive centrifugations of 
monoclonal antibodies against HSP72 (clone 




C92F3A-5, Enzo Life Sciences, NY, USA) on Vivaspin 
concentrator filters with a molecular weight cut-off 
(MWCO) threshold of 30 kDa (GE Healthcare, WI, 
USA) in the presence of 2 ml of HBS (pH=6.7). The 
resulting solutions were incubated for 45 min with 
N-succinimidyl S-acetylthioacetate (SATA, Sig-
ma-Aldrich, MO, USA) using an antibody:SATA ratio 
of 1:80. Free SATA was removed by three consecutive 
centrifugations in Vivaspin filters with a 30 kDa 
MWCO in the presence of 4 ml of HBS (pH=6.7), and 
SATA-treated antibodies were incubated for 60 min in 
a hydroxylamine solution (50 mM; 1:10 
H3NO:antibody ratio, Sigma-Aldrich, MO, USA). This 
solution was added to maleimide liposomes (50 µg of 
protein per µmol of lipid) and incubated overnight at 
4°C. Uncoupled antibody units were removed by ul-
tra-centrifugation at 65000 rpm for 45 min, suspend-
ing the resulting HSP72-coupled liposomes in HBS 
(pH=7.4) and storing them at 4 °C until use. 
Tissue samples 
Rat brains were quickly extracted after sacrifice 
for proteomic and Western-blotting studies and sliced 
into 5x 2-mm-thick sections (rostro-caudal direction, 
starting at 1 mm from the rhinal fissure) and im-
mersed for 5-10 min in a saturated solution of Tri-
phenyl Tetrazolium Chloride (Parnreac Química, 
Barcelona, Spain) in 1x phosphate-buffered saline 
(Gibco Life Technologies, CA, USA), to stain dead 
cells (infarct core) in white (figure 1a). For immuno-
histological studies, animals were transcardially per-
fused with a lethal dose of anesthetic (Sevofluorane at 
8%) in 100 ml of saline followed by 300 ml of 4% for-
maldehyde (BDH Prolabo, VWR, PA, USA). Brains 
were then extracted and sliced in 4x 3-mm-thick 
blocks (rostro-caudal direction, starting at 1 mm from 
the rhinal fissure). Tissue blocks were immersed in 4% 
formaldehyde (overnight), 20% sucrose (24 h), and 
finally in liquid N2-cooled pentane. Frozen brain 
blocks were preserved at -80 °C until further use. 
Proteomic studies  
Proteins from peri-infarct and contralateral 
(control) tissue strips (manually dissected from 
TTC-stained brain sections, figure 1a) were extracted 
using the ProteoExtract® Native Membrane Protein 
Extraction Kit (Calbiochem Merck KGaA, Darmstadt, 
Germany) following the manufacturer’s instructions. 
Protein contents were quantified with the modified 
Bradford method [48]. A series of 72 proteomic gels 
were used for 2D electrophoresis (2 replicas x 6 ani-
mals x 2 tissue samples x 3 protein fractions), each 
containing 40 µg of protein. The proteins were sepa-
rated by isoelectric point (1st dimension) and molecu-
lar weight (2nd dimension) with 17 cm 3-10 NL IPG 
strips (BioRad, CA, USA) and 12.5% polyacrylamide 
gels on a ETTAN-DALTSIX system (GE Healthcare, 
WI, USA), respectively. Procedures used for 2D elec-
trophoresis and data processing were performed as 
described by Brea et al. [49].  
Immunoblotting studies 
Twelve additional 2D electrophoresis gels (2 
replicas x 2 animals x 3 protein fractions) were pre-
pared as described above. The separated proteins 
were transferred from those gels to low-fluorescence 
PVDF membranes (Millipore, MA, USA) in semi-dry 
conditions at 15 V for 45 minutes, blocked in 5% 
non-fat dry milk (2 h, room temperature) and incu-
bated overnight with mouse monoclonal anti-rat 
HSP70 antibody (1:1000, Abcam, MA, USA). Protein 
loads were verified by simultaneous incubation with 
rabbit polyclonal anti-rat β-actin (1:3000, Abcam, MA, 
USA). Detection was achieved by Cy3-labelled goat 
anti-mouse (1:3000, GE, Barcelona, Spain) or 
Cy5-labelled goat anti-rabbit (1:3000, GE, Barcelona, 
Spain) secondary antibodies. Gels were scanned on a 
Molecular Imager FX Pro-plus (BioRad, CA, USA) for 
data analysis with PDQuest software package (Bio-
Rad, CA, USA). 
Immunohistochemistry studies  
Frozen brain blocks were sliced in 10 µm coronal 
sections with a Tissue-Tek Cryo3 Cryostat (Sakura 
Finetek, Alphen aan dem Rijn, The Netherlands) and 
incubated with 3% H2O2 and 10% methanol in PBS to 
block endogenous peroxidases, and with 3% normal 
serum and 0,2% Triton X-100 in PBS to block unspe-
cific binding sites.  
For light microscopy, the inducible form of 
HSP70 was revealed by a 1 h incubation with a 1:50 
dilution of HSP70/HSP72 mAb (C92F3A-5) primary 
antibody (Enzo life sciences, NY, USA), while non-
specific inducible and constitutive HSP70 protein 
mixtures were identified by a 1 h incubation with a 
1:50 dilution of anti-HSP70 antibody (ab5439, 1:50 
dilution Abcam, Cambridge, MA). Samples were 
further processed with biotin-conjugated secondary 
anti-rabbit antibody (1:200; Vector Laboratories, CA, 
USA) and streptavidin-conjugated peroxidase (Vec-
statin Abc kit, Vector Laboratories, CA, USA). Color 
was developed by the addition of DAB (Dako, 
Glostrup, Denmark).  
For in vitro fluorescence studies, HSP72 was la-
beled with HSP70/HSP72 mAb (C92F3A-5; 1:50 dilu-
tion; Enzo Life Sciences, NY, USA) and bio-
tin-conjugated anti-mouse secondary antibody 
(BA-2001; 1:200; Vector Laboratories CA, USA) at-
tached to DyLight 549 Streptavidin (SA-5549-1; 1:200; 
Vector Laboratories, CA, USA) as the secondary an-




tibody. Neurons and astrocytes were labeled with 
anti-FOX3 (ab104225; 1:50 dilution; Abcam, MA, USA) 
or polyclonal anti-GFAP (G4546; 1:100: Sig-
ma-Aldrich, MO, USA), respectively, as primary an-
tibodies, directly attached to DyLight 488 horse an-
ti-rabbit IgG antibody (DI-1488; 1:200; Vector Labor-
atories, CA, USA). 
Cell cultures  
Primary cultures of rat astrocytes were obtained 
from 1-day-old rats by disaggregation and digestion 
of their freshly extracted brains following the method 
of McCarthy et al [50]. Cultures were maintained in 
flasks or dishes (BD Biosciences, CA, USA) in a hu-
midified (97%) incubator at 37 °C and 95:5 air:CO2 
atmosphere. Confluence levels were typically main-
tained at 70-80%. Upregulation of HSP72 proteins in 
the membrane of cultured astrocytes (in vitro model 
for peri-infarct tissue) was achieved following the 
process described by de Freitas et al [41].  
Microscopy 
Fluorescence and light microscopy images were 
acquired on a IX-51 microscope (Olympus GMBH, 
Hamburg, Germany) attached to a DS-U2 LCD cam-
era (Nikon Instruments, NY, USA).  
MR imaging 
Magnetic resonance imaging (MRI) studies were 
conducted on a 9.4 T MR system (Bruker Biospin, Et-
tlingen, Germany) with 440 mT/m gradients, using a 
combination of a linear birdcage resonator of 7 cm of 
diameter for signal transmission and a 2x2 arrayed 
surface coil for signal detection. 
T1-weighted images (T1w) were typically ac-
quired using a RARE sequence (rare factor=4, aver-
ages=2) with an effective echo time of TE=22 ms and a 
repetition time of TR=900 ms (flip angle = 90°). The 
whole brain was covered with 14 consecutive axial 
slices of 1 mm thickness with a field-of-view (FOV) of 
19.2x19.2 mm (with saturation bands to suppress the 
signal outside the brain) and an in-plane resolution of 
100 microns (192x192 points matrix). When required, 
coronal images where acquired using a FOV of 
32x19.2 mm, keeping the same spatial resolution. The 
FOV was adapted to the required size for MR imaging 
of solutions (placed in 1.5 ml Eppendorf tubes) in in 
vitro studies. To obtain T1 maps, we used the same 
RARE sequence following a saturation-recovery ap-
proach [51] to acquire a series of 12 images with repe-
tition times ranging from 250 ms to 12 s (exponentially 
distributed). 
T2-weighted images (and maps) were typically 
acquired using a multi-slice multi-echo (MSME) se-
quence (averages=2) with a train of 16 echoes (TE=9.5 
ms) and a repetition time of TR=2.5 s (flip angle = 90°). 
The spatial orientations and resolutions were the 
same as described above. 
Apparent diffusion coefficient (ADC) maps were 
obtained from diffusion-weighted images (DWI) by 
pixel-by-pixel mono-exponential fitting of a series of 7 
images acquired using an echo-planar sequence 
(DWI-EPI) with the following acquisition parameters: 
field-of-view 19.2x19.2 mm2 (saturation bands out of 
this FOV), an image matrix of 128x128 point (in-plane 
resolution 0.15 mm/pixel), 14 consecutive slices of 1 
mm thickness, repetition time = 4 s, echo time = 30 ms, 
and diffusion b values of 0, 100, 300, 600, 800, 1000, 
and 1400 s/mm2.  
ADC maps were constructed using ParaVision 
5.1 software from Bruker Biospin (Ettlingen, Germa-
ny), while proton density images and T1 and T2 re-
laxation maps were calculated by a pixel-by-pixel 
mono-exponential fitting of the data with 
self-developed applications for Image-J (Rasband, 
W.S., ImageJ, U. S. National Institutes of Health, Be-
thesda, Maryland, USA, http://imagej.nih.gov/ij/, 
1997-2012). 
Lesion sizes from all animals were calculated 
from ADC maps (pre-treatment) or from T2 paramet-
ric maps (days 1, 3 and 7 post-treatment) by manual 
selection of the (hyperintense) lesion area on each of 
the 14 acquired brain slices per brain, and the areas 
calculated for the 14 measured 1-mm-thick brain slic-
es were added. Considering the large increase in T2 
values induced by an ischemic lesion and the rela-
tively low transversal relaxivity of our liposomes 
(r2=8.38 mM-1s-1), the potential presence of 
Gd-liposomes in the brain did not significantly affect 
the measure of lesion volumes. 
MRI maps of the distribution of liposomes 
T1 parametric maps of control (saline-treated) 
animals were used to obtain histograms of T1 values 
for healthy tissue (pink bars in figure 5a, distribution 
centered at T1=2.47 s with FWHM=0.48 s) and is-
chemic tissue (blue bars in figure 5a, distribution 
centered at T1=2.80 s with a FWHM of 0.54 s). 
The distribution of T1 values for brain tissue re-
gions that contain Gd-doped liposomes in vivo cannot 
be directly calculated because the exact concentration 
of liposomes in each region of the brain remains un-
known. Thus, an approximation has to be made to 
estimate the distribution. We followed an approach 
based on obtaining the T1 maps of animals receiving 
intraparenchymal injections of liposomes (study pre-
sented in figure 3). After the injection of liposomes, a 
gradient of concentrations was established with the 
distance from the injection point. The selection of a 
reasonable proportion of tissue around the injection 
site allowed the generation of a histogram of pixels 




that contain a wide range of T1 values based on the 
concentration of liposomes on each pixel of the tissue 
that dilutes to zero with the distance to the injection 
point (green bars in figure 5a, centered at T1=2.25 s 
with FWHM=0.32 s). This is a limitation of the present 
study and the most critical part of the image analysis 
described here (and graphically summarized in figure 
5b). Future studies will include the preparation of 
liposomes with higher r1 relaxivity to allow better 
characterization of liposome-loaded tissue (resulting 
in fewer overlapping of populations in the histo-
gram).  
For image analysis, we first obtained T1 para-
metric maps of each brain slice (pixel-by-pixel 
mono-exponential fitting) for all animals. Then, a 
colored look-up table (LUT) was applied to empha-
size differences in T1 values. For the third step, noisy 
maps were smoothed using a Gaussian filter (r=0.6). 
Subsequently, a clipping filter was used to eliminate 
pixels with T1 ≥ 2.25 s, which corresponds to the peak 
T1 distribution of liposome-loaded tissues (green bars 
in figure 5a). The selection of this threshold is the 
most critical step of our analysis and represents a 
limitation to this work because the tails of the healthy 
tissue and liposome-loaded tissue distributions of T1 
values overlap. Thus, pixels corresponding to the left 
tail of the distribution of T1 values for healthy tissue 
may be counted as liposomes-containing tissue (false 
positives) while pixels of the right tail of the distribu-
tion of liposomes-containing tissue are obviated (false 
negatives). Our work must be improved in the future 
through more complex models for image analysis, 
which may not be necessary if optimized liposomal 
designs are used to achieve higher relaxometries 
(lower T1 values), reducing the overlap of the two 
aforementioned histograms.  
Assuming that the results of this last step are 
acceptable (at least for proof-of-principle purposes), 
we proceeded to enhance the contrast of the remain-
ing pixels against the background by rescaling the 
images. Finally, images of “liposomes” (low T1 pixels) 
were overlaid with the corresponding proton density 
images of the brain, and a clustering process was 
performed to remove groups of n<3 pixels (consid-
ered random noise).  
Statistical analysis 
Quantitative data are always presented as the 
mean ± standard deviation in this work. Differences 
between pairs were compared with Student’s t-test. 
Differences among multiple groups (in vivo studies) 
were compared with ANOVA tests. Differences were 
considered statistically significant when a level of 
p<0.05 was achieved. 
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